Zobrazeno 1 - 10
of 53 354
pro vyhledávání: '"OPEN-LABEL"'
Autor:
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXI
Externí odkaz:
https://doaj.org/article/1259403985ce47a0a402e64210800be8
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Obesity is a major public health problem worldwide. Different approaches are known to face this problem, for example, dieting, surgery, or drug interventions. It has also been shown that placebos may help to reduce weight and hunger feelings
Externí odkaz:
https://doaj.org/article/690e8fa00b544da68a2d3ccd448b4075
Publikováno v:
European Journal of Investigation in Health, Psychology and Education, Vol 14, Iss 8, Pp 2435-2444 (2024)
Studies with adults and school children have shown that placebos can enhance motivation and performance in physical activities. This study aimed to investigate whether similar effects are present in kindergarten-aged children. A total of 101 children
Externí odkaz:
https://doaj.org/article/1a7ef3cbe0764290b9f47d9cd0a49746
Autor:
Leighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, Hagit Baris Feldman, Andrew Yaworsky, Paolo Medrano, Voranush Chongsrisawa, Taylor Brackin, Lorah Perlee, Marisa Walker, Sharanya Pradeep, Michael J. Lenardo, Olivier A. Harari, Jessica J. Jalbert
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-15 (2024)
Abstract Background CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease is ultra-rare (
Externí odkaz:
https://doaj.org/article/f82a2fd52091428c9e80233cbb076e5b
Autor:
Mika Komori, Akichika Ozeki, Yuka Tanji, Eriko Kamiki, John H. Krege, Lily Qian Li, Shiho Suzuki, Mamoru Shibata, Takao Takeshima
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background The objective of this analysis was to gain new insights into the patient characteristics and other factors associated with lasmiditan usage and clinical outcomes under conditions resembling the real-world setting. Methods This was
Externí odkaz:
https://doaj.org/article/c8c8471e2b9e4c4498c739468c55b899
Autor:
Michael Schaefer, Sören Enge
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Passing the driving school test can be very challenging, especially in big cities, where up to 52% of all students fail this test. Consequently, many learner drivers experience stress and anxiety. For some learner drivers these feelings can
Externí odkaz:
https://doaj.org/article/4cb1e39fbba843ec854e84db6cd2ebef
Autor:
Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult pat
Externí odkaz:
https://doaj.org/article/bd0898e3f87142f18fa40e8716ed1f0d
Autor:
Hye Sung Han, Won-Serk Kim, Yang Won Lee, Chong Hyun Won, Wooshun Lee, Sun Young Choi, Beom Joon Kim
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Purpose Following the introduction of new type of botulinum toxin (MBA-P01), a recent phase 3 study demonstrated that MBA-P01 showed comparable efficacy and safety to onabotulinumtoxin A for reducing glabellar lines. The primary objective of this stu
Externí odkaz:
https://doaj.org/article/592aa0691724454aa59a7add22e122ad
Autor:
Kirk N. Campbell, Loreto Gesualdo, Edward Murphy, Michelle N. Rheault, Tarak Srivastava, Vladimir Tesar, Radko Komers, Howard Trachtman
Publikováno v:
Kidney Medicine, Vol 6, Iss 6, Pp 100833- (2024)
Rationale & Objective: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) examined in the ongoing phase 2 DUET trial for focal segmental glomerulosclerosis (FSGS). In the DUET 8-week
Externí odkaz:
https://doaj.org/article/0ba95d86e588438faad9ebaf7857f509
Autor:
Schienle A, Seibel A
Publikováno v:
Psychology Research and Behavior Management, Vol Volume 17, Pp 393-400 (2024)
Anne Schienle, Arved Seibel Department of Clinical Psychology, University of Graz, Graz, AustriaCorrespondence: Anne Schienle, Email anne.schienle@uni-graz.atBackground: Open-label placebos (OLPs), honestly prescribed regarding their inert nature, ha
Externí odkaz:
https://doaj.org/article/97bcf30d23584b999c0f06d6f116300f